Status:
COMPLETED
Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment
Lead Sponsor:
University of Illinois at Chicago
Collaborating Sponsors:
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Conditions:
Internalizing Psychopathologies (IPs) Depression and Anxiety
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Internalizing psychopathologies (IPs) involving depression and anxiety are among the most prevalent, costly and disabling illnesses. Treatments for IPs are available but the extent to which individual...
Eligibility Criteria
Inclusion
- Generally medically and neurologically healthy
- Chief complaint(s) of "anxiety, worry, and/or depressed mood
Exclusion
- Current or past manic/hypomanic episode or psychotic symptoms
- Suicidal ideation
- Presence of contraindications (e.g., history of SSRI adverse events) or prior history of SSRI resistance (no response to \> 2 SSRI trials with adequate duration and dose)
- Obsessive compulsive disorder (OCD)
- Current cognitive dysfunction (traumatic brain injury, mental retardation, dementia)
- Current alcohol and substance dependence
- Ongoing therapy/medication treatment of any kind outside of this study
Key Trial Info
Start Date :
December 13 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2018
Estimated Enrollment :
271 Patients enrolled
Trial Details
Trial ID
NCT01903447
Start Date
December 13 2013
End Date
February 21 2018
Last Update
October 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60608